Boehringer calls it quits on Gilotrif expansion effort in head and neck cancer

Boehringer was hoping to get some more mileage out of its targeted lung cancer med Gilotrif. But those hopes were dashed when a data monitoring committee advised the German drugmaker to halt a clinical trial.

The German drugmaker stopped two Phase III trials evaluating the med in patients with locally advanced head and neck cancer who showed no signs of disease after chemo. The company had hoped to show that post-chemo Gilotrif treatment would help keep the cancer from returning, but an independent data monitoring committee thought otherwise.

The committee “made the assessment that it would be highly unlikely” that Boehringer’s trials would produce a significant advantage for the company’s product over placebo, Boehringer said Monday.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

While Boehringer’s expansion effort may have been thwarted, it has others in the works. As the company noted, it’s still developing the med in other solid tumors--an effort it hopes will boost Gilotrif, which boasts approvals in distinct types of EGFR mutation-positive non-small cell lung cancer (NSCLC) and advanced squamous cell carcinoma of the lung.

And Gilotrif could use that boost. It last year picked up a new EGFR competitor in AstraZeneca’s Iressa, which staged a comeback with a first-line lung cancer nod after four years off the market. And it was already up against Tarceva, a therapy from cancer giant Roche.

Meanwhile, though, Boehringer is focusing its efforts on areas other than cancer, too. It recently agreed to trade away its consumer health assets to Sanofi in exchange for the French drugmaker’s animal health unit. And it’s been making waves in diabetes with partner Eli Lilly; last year, the pair’s Jardiance became the first diabetes med to show it could cut the combined rate of heart attack, stroke and cardiovascular death, and the tandem now plans to test the drug as a treatment for heart failure.
 

Related Articles:
Aiming for top dog status, Sanofi and Boehringer swap animal and consumer health units
Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV events
Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto
AZ's Iressa gets back in the game with first-line FDA approval in lung cancer

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.